Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129431 | 0.94 | NR1H4 (0.63) | NR1H4LIFR | |
| SCHEMBL2128864 | 0.91 | NR1H4 (0.67) | NR1H4LIFR | |
| SCHEMBL2128786 | 0.89 | NR1H4 (0.78) | NR1H4LIFR | |
| SCHEMBL2128604 | 0.89 | NR1H4 (0.80) | NR1H4LIFR | |
| SCHEMBL2129745 | 0.85 | NR1H4 (0.64) | NR1H4LIFR | |
| SCHEMBL2131102 | 0.85 | NR1H4 (0.67) | NR1H4LIFR | |
| SCHEMBL4435997 | 0.84 | NR1H4 (0.71) | NR1H4LIFR | |
| SCHEMBL2128448 | 0.84 | NR1H4 (0.69) | NR1H4 | |
| SCHEMBL4427073 | 0.83 | NR1H4 (0.69) | NR1H4LIFR | |
| SCHEMBL2131718 | 0.83 | NR1H4 (0.68) | NR1H4LIFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084147-B1 | HETEROCYCLIC FXR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2084147-B1 | HETEROCYCLIC FXR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-04-25 | — | — | EP | disclosed |
| US-20100184809-A1 | Heterocyclic FXR Binding Compounds | PHENEX PHARMACEUTICALS AG (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184809-A1 | Heterocyclic FXR Binding Compounds | PHENEX PHARMACEUTICALS AG (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184809-A1 | Heterocyclic FXR Binding Compounds | PHENEX PHARMACEUTICALS AG (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2084147-A1 | HETEROCYCLIC FXR BINDING COMPOUNDS | Phenex Pharmaceuticals AG (DE) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008025540-A1 | HETEROCYCLIC FXR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2008-03-06 | — | — | WO | disclosed |
| EP-1894924-A1 | Heterocyclic FXR binding compounds | Phenex Pharmaceuticals AG (DE) | 2008-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184809-A1 | Heterocyclic FXR Binding Compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885LIFR 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.